Conectar
To shed new light on the management practice and needs for support, mentoring and continuous education of nurse managers (head nurses and assistant head nurses) during and since the COVID-19 pandemic to identify the innovative strategies they put in place to mobilise teams and foster a healthy work environment.
A multi-centre exploratory descriptive study with a qualitative descriptive exploratory design was used.
10 focus groups held between December 2021 and July 2022, five from a Canadian healthcare centre and five from a Swiss healthcare centre, were conducted with 35 nurse managers. The data were analysed using thematic analysis.
Six central themes emerged: (1) A difficult context to navigate: Continuous adaptation necessary to navigate through difficulties and a rapidly changing context, (2) Maintaining a visible presence and engaging in active listening with team members to promote commitment, motivation and mobilisation, (3) Frequent short meetings, instant and transparent communication, (4) Role legitimacy and recognition, along with continuous professional development, (5) Integration and cohesion among team members, and the quality of care and (6) Shared leadership: A key strategy to prioritise.
The present study offers unique insights into the innovative strategies nurse managers have put in place to ensure the optimal functioning of their care team, to foster a positive work climate, and to ensure the commitment, motivation and mobilisation of their teams. A shared leadership approach appears to be a key lever of action to optimally tackle the present and future needs and challenges of nurse managers.
This study highlights key managerial strategies that can be beneficial in all contexts or during future crises, ultimately helping healthcare organisations and nurse managers have a better understanding of their role and influence.
Consolidated Criteria for Reporting Qualitative Research (COREQ).
No patient or public contribution.
Establishing comparability between measured outcomes in clinical trials poses a significant obstacle for systematic reviewers. Core outcome sets (COSs) were developed to address this issue. The macular degeneration (MD) COS is designed to standardise outcome measurement across clinical trials for MD. This study investigates the uptake of the MD COS in standardising outcome measurement across clinical trials.
Cross-sectional analysis
We conducted a search on ClinicalTrials.gov to locate MD clinical trials that were registered 5 years prior to COS publication through the search date of 26 June 2023 and obtained a pool of 2152 registered studies. After applying various inclusion and exclusion criteria, we analysed 159 trials. We then analysed the COS uptake using an interrupted time series analysis (ITSA) and performed performed analyses of variance (ANOVAs) and Pearson correlations to evaluate associations between trial characteristics and outcome measurement.
ITSA showed no significant change in uptake following the MD COS (2016): mean percentage of completion of the COS increased by 0.24% per month before publication (p=0.27) and by 0.07% per month after publication (p=0.62), indicating no meaningful post-publication slope change in COS use. For context, visual acuity was most commonly measured, while several patient-reported and disutility domains were infrequently captured.
No discernible patterns in COS usage for MD trials were observed. We recommend further collaboration between regulators and COS developers to help with COS uptake. Additionally, we suggest that further studies analyse adherence to COSs in respect to regulatory recommendations.
by Nailya Ibragimova, Arailym Aitynova, Seitzhan Turganbay, Marina Lyu, Alexandr Ilin, Tamari Gapurkhaeva, Galina Ponomareva, Karina Vassilyeva, Diana Issayeva, Amirkan Azembayev, Serzhan Mombekov, Aralbek Rsaliyev, Nurgul Sikhayeva, Yergali Abduraimov, Saki Raheem
Iodine-based antiseptics are essential in wound care but are often limited by cytotoxicity, instability, and rapid iodine release. Novostron is a novel polymer–iodine complex incorporating dextrin, polyvinyl alcohol, and metal ions, designed to enable controlled iodine release. Structural integrity and composition were confirmed by ¹H and 13C NMR spectroscopy and physicochemical analysis, indicating a molecular weight of ~9500 g/mol, a pH of 4.23, and an iodine content of 8.13%. Pharmacokinetic analysis in rabbits demonstrated that following a single dermal application, systemic iodine absorption was minimal, with peak blood iodine concentrations remaining within physiological limits and rapid elimination within 24 hours. Evaluation of thyroid function revealed no significant changes in serum T₃, T₄, or TSH levels compared with those of the controls, confirming that topical application of Novostron does not disrupt thyroid homeostasis. In compliance with OECD guidelines in rabbits, guinea pigs, and rats, Novostron showed no signs of dermal irritation, skin sensitization, or systemic toxicity (LD₅₀ > 2000 mg/kg). In a rat cotton pellet granuloma model, Novostron significantly reduced the inflammatory mass (23.65% inhibition), supporting its anti-inflammatory potential. In a murine burn model, Novostron accelerated wound contraction (25.95% at day 10), increased epidermal thickness, and enhanced collagen deposition (~44%), outperforming controls and matching or exceeding betadine. These findings suggest that Novostron promotes tissue repair by modulating inflammation. Overall, Novostron demonstrated a favourable preclinical safety and efficacy profile, and its polymer–iodine composition, which enables controlled release and localized activity highlights its potential as a promising topical therapeutic. However, the study was limited to animal models and short-term observation; further long-term and clinical investigations are needed to confirm its translational potential in human wound healing.To explore the lived experience following Roux-en-Y gastric bypass surgery of eight men and women in the South of England who had undergone surgery a minimum of 12 months prior.
This phenomenologically based qualitative study utilised Interpretative Phenomenological Analysis (IPA) as a framework for the analysis and exploration of participants' lived experiences.
Semi-structured individual interviews were conducted with eight men and women in the South of England in 2017.
Interpretative Phenomenological Analysis revealed four superordinate themes: Managing change and uncertainty; The affective experience of change; The post-operative body within its relational context; and The presence and absence of appropriate support.
Participants described the complex nature of the post-operative experience and highlighted the deeply personal nature of the adjustment required following surgery. The process of change and adjustment does not represent a smooth transition from pre- to post-operative life, and the experience of weight loss is intertwined with relationships that require patients to renegotiate the ways in which they understand themselves within social encounters.
The clinical significance of this study lies in its support for the contribution that an existential phenomenological approach can offer in supporting individuals who choose to have bariatric surgery through its acknowledgment of the body as a site of experience which is situated within a person's wider social, cultural and historical world. These findings contribute an in-depth appreciation of the biopsychosocial experiences of individuals following Roux-en-Y gastric bypass surgery that can be applied in nursing practice to better inform the development of appropriate ways in which to support the overall wellbeing of individuals who made the decision to undergo bariatric surgery.
Limited patient involvement was incorporated, focusing on feedback on the interview process.
Cystic fibrosis (CF) is a genetic condition of impaired membrane electrolyte transport and is characterised by defects in the production and function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein. Ground-breaking CFTR modulator therapy has resulted in a notable shift in the clinical presentation and progressive nature of CF, across both pulmonary and extrapulmonary systems. Access to CFTR modulator therapies in people with CF is occurring in a staged, descending age process, with clinical trials focusing primarily on safety and efficacy. There is a lack of robust, real-world longitudinal data on CFTR modulator therapy in infants and young children where extrapulmonary outcomes such as growth, micronutrient status and pancreatic function are the key focus.
Pancreatic, nutritional and clinical outcomes in children 0–5 years with CF during the first 2 years of CFTR modulator therapy (PaNC) is a prospective cohort study involving all eight tertiary paediatric CF centres in Australia. Infants and children 4 months to 5 years of age who are eligible for elexacaftor/tezacaftor/ivacaftor (ETI) or ivacaftor (IVA) meet the inclusion criteria for PaNC, with a total eligible cohort of 303 children at the commencement of recruitment. The primary outcomes are change in weight-for-length/body mass index z score and change in serum micronutrient status, at 6–12 monthly intervals, during the first 2 years of treatment with ETI or IVA. Secondary outcomes include change in exocrine pancreatic function, measured by faecal elastase-1, change in the use and dose of pancreatic enzyme replacement therapy, nutritional and gastrointestinal therapies and change in sweat chloride levels. Linear mixed modelling will be used to analyse primary and secondary endpoints. This protocol is reported in accordance with ‘The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement’ reporting guidelines.
Overarching governance and ethics approval has been granted by Monash Health Human Research Ethics Committee, in addition to all eight sites receiving site-specific authorisation approvals prior to the commencement of recruitment. Opportunities for CF consumers to be involved in targeted dissemination plans will be initiated via CF Australia at the completion of the study period. Additionally, a summary of non-identifiable results will be provided to CF consumers and CF healthcare providers via scientific and lay conferences and via peer-reviewed journals.
ACTRN12624001185550; Pre-results.
FreshRSS 